These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 16039851

  • 1. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
    Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L.
    Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4370-4. PubMed ID: 16039851
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ.
    J Med Chem; 1999 Feb 25; 42(4):677-90. PubMed ID: 10052975
    [Abstract] [Full Text] [Related]

  • 3. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
    Chambers MS, Street LJ, Goodacre S, Hobbs SC, Hunt P, Jelley RA, Matassa VG, Reeve AJ, Sternfeld F, Beer MS, Stanton JA, Rathbone D, Watt AP, MacLeod AM.
    J Med Chem; 1999 Feb 25; 42(4):691-705. PubMed ID: 10052976
    [Abstract] [Full Text] [Related]

  • 4. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
    Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD.
    J Med Chem; 1998 Apr 09; 41(8):1218-35. PubMed ID: 9548813
    [Abstract] [Full Text] [Related]

  • 5. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
    Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S.
    J Med Chem; 1997 Nov 21; 40(24):3974-8. PubMed ID: 9397179
    [Abstract] [Full Text] [Related]

  • 6. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
    Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersad V, Prisinzano T, Glennon RA.
    J Med Chem; 1998 Jun 18; 41(13):2243-51. PubMed ID: 9632357
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA, Sallander J, Benhamú B, Porras E, Campillo M, Pardo L, López-Rodríguez ML.
    J Med Chem; 2009 Apr 23; 52(8):2384-92. PubMed ID: 19326916
    [Abstract] [Full Text] [Related]

  • 8. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B, Bonnaud B, Funes P, Jubault N, Koek W, Assié MB, Cosi C, Kleven M.
    J Med Chem; 1999 May 06; 42(9):1648-60. PubMed ID: 10229633
    [Abstract] [Full Text] [Related]

  • 9. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V.
    J Med Chem; 2004 Dec 16; 47(26):6616-24. PubMed ID: 15588097
    [Abstract] [Full Text] [Related]

  • 10. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A.
    J Med Chem; 1999 May 06; 42(9):1556-75. PubMed ID: 10229626
    [Abstract] [Full Text] [Related]

  • 11. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
    Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):1781-95. PubMed ID: 15771424
    [Abstract] [Full Text] [Related]

  • 12. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P, Sohn D, Leideborg R, Caldirola P, Zlatoidsky P, Hanson S, Mohell N, Rosqvist S, Nordvall G, Johansson AM, Johansson R.
    J Med Chem; 2004 Jul 29; 47(16):3927-30. PubMed ID: 15267230
    [Abstract] [Full Text] [Related]

  • 13. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.
    Ward SE, Eddershaw PJ, Scott CM, Gordon LJ, Lovell PJ, Moore SH, Smith PW, Starr KR, Thewlis KM, Watson JM.
    J Med Chem; 2008 May 22; 51(10):2887-90. PubMed ID: 18433113
    [Abstract] [Full Text] [Related]

  • 14. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF, Koolhaas JM.
    Eur J Pharmacol; 2005 Dec 05; 526(1-3):125-39. PubMed ID: 16310183
    [Abstract] [Full Text] [Related]

  • 15. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
    Glennon RA, Hong SS, Bondarev M, Law H, Dukat M, Rakhi S, Power P, Fan E, Kinneau D, Kamboj R, Teitler M, Herrick-Davis K, Smith C.
    J Med Chem; 1996 Jan 05; 39(1):314-22. PubMed ID: 8568822
    [Abstract] [Full Text] [Related]

  • 16. Modification of the structure of 4, 6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: synthesis and their 5-HT2A receptor activity.
    Paluchowska MH, Bojarski AJ, Bugno R, Charakchieva-Minol S, Wesołowska A.
    Arch Pharm (Weinheim); 2003 Apr 05; 336(2):104-10. PubMed ID: 12761763
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationship studies of CNS agents. Part 10(1): 1-Aryl-2-[3-(4-aryl-1-piperazinyl)propyl]-1,4-dihydro-3(2H)-isoquino linones: two modes of the interaction with the 5-HT1A receptor site.
    Mokrosz JL, Bojarski AJ, Maćkowiak M, Bielecka Z, Boksa J.
    Pharmazie; 1994 May 05; 49(5):328-33. PubMed ID: 8016178
    [Abstract] [Full Text] [Related]

  • 18. 5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
    Barf TA, de Boer P, Wikström H, Peroutka SJ, Swensson K, Ennis MD, Ghazal NB, McGuire JC, Smith MW.
    J Med Chem; 1996 Nov 22; 39(24):4717-26. PubMed ID: 8941384
    [Abstract] [Full Text] [Related]

  • 19. Identification of a potent and selective 5-HT1B receptor antagonist.
    Wyman PA, Marshall HR, Flynn ST, King RJ, Thompson M, Smith PW, Hadley MS, Price GW, Scott CM, Dawson LA.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4708-12. PubMed ID: 16153839
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
    Chloń G, Pawłowski M, Duszyńska B, Szaro A, Tatarczńska E, Kłodzińska AL, Chojnacka-Wójcik E.
    Pol J Pharmacol; 2001 Nov 01; 53(4):359-68. PubMed ID: 11990082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.